bluuebunny/crossref_metadata_2025_split huggingface dataset:
Treatment of Large Knee Osteochondral Lesions With a Biomimetic Scaffold
Authors: Berruto Massimo , Delcogliano Marco , de Caro Francesca , Carimati Giulia , Uboldi Francesco , Ferrua Paolo , Ziveri Giovanni , De Biase Carlo Felice 
Published: April 2014

Background: Osteochondral knee lesions represent a challenging condition encountered by orthopaedic surgeons. A variety of methods have been developed to repair articular cartilage defects. However, these techniques are limited by donor site morbidity or by the requirement for a staged procedure. Purpose: To assess the effectiveness of a biomimetic osteochondral scaffold for the treatment of large osteochondral knee lesions. Study Design: Case series; Level of evidence, 4. Methods: From 2009 to 2011, a total of 49 patients affected by isolated large osteochondral knee lesions (mean [± SD] size, 4.35 ± 1.26 cm2) were treated with the biomimetic scaffold. Patients were evaluated using the International Knee Documentation Committee (IKDC), Tegner, and visual analog scale (VAS) pain scores, as well as magnetic resonance imaging (MRI) up to 3-year follow-up. The MOCART (magnetic resonance observation of cartilage repair tissue) score was performed to analyze different variables. Biopsies were carried out in 5 patients. Four of the 5 second-look arthroscopies and biopsies were performed on patients with failed results because of ethical issues. Results: The mean IKDC subjective score increased significantly from 45.45 ± 19.29 preoperatively to 70.86 ± 18.08 at 1-year follow-up and to 75.42 ± 19.31 at 2-year follow-up ( P < .001). The IKDC objective score changed from 50% normal and nearly normal knees before treatment to 89.79% at the 2-year follow-up. There was a statistically significant improvement ( P < .005) in VAS score from the preoperative level (6.69 ± 1.88) to the 2-year follow-up (1.96 ± 2.47). Tegner scores increased ( P < .001) from the preoperative value (2.20 ± 0.67) to the 2-year follow-up (4.9 ± 1.73) without achieving preinjury level. A correlation was found between the IKDC subjective score and age ( P < .001, r = −0.497, ρ = −0.502). Patients affected by osteochondritis dissecans (OCD) achieved a statistically significantly better outcome ( P < .05). A subgroup of 19 competitive athletes showed a statistically significantly improvement ( P < .001) in the subjective IKDC (86.5 ± 13.2) compared with the nonathletic subpopulation (69.03 ± 19.41) at the 2-year follow-up. The MRI findings of 30 patients were available at 2-year follow-up: 70% showed complete filling of the lesion, 63.3% had an intact articular surface, and 86% had mild or no effusion. In all cases, in dual T2-weighted fast spin echo sequence, the repair tissue showed a hyperintensive signal with respect to the surrounding subchondral bone; however, no edema was observed. Conclusion: The study findings indicate that the biomimetic scaffold that was investigated is an off-the-shelf, cell-free, and cost-effective implant that can regenerate either cartilage or subchondral bone. The scaffold allows a 1-step surgical procedure that can be used for osteochondral lesions, OCD, and in some cases osteonecrosis.
Surgical Predictors of Early Revision Surgery After Anterior Cruciate Ligament Reconstruction
Authors: Andernord Daniel , Björnsson Haukur , Petzold Max , Eriksson Bengt I. , Forssblad Magnus , Karlsson Jón , Samuelsson Kristian 
Published: April 2014

Background: An important objective of anterior cruciate ligament (ACL) registries is to detect and report early graft failure and revision surgery after ACL reconstruction. Purpose: To investigate surgical variables and identify predictors of revision surgery after ACL reconstruction. Study Design: Prospective cohort study; Level of evidence, 2. Methods: This prospective cohort study was based on data from the Swedish National Knee Ligament Register during the years 2005 through 2011. Eight surgical variables were investigated: graft selection, graft width, single-bundle or double-bundle techniques, femoral graft fixation, tibial graft fixation, injury-to-surgery interval, injuries to menisci, and injuries to cartilage. The primary endpoint was the 2-year incidence of revision surgery. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated and adjusted for confounders by use of multivariate statistics. Results: A total of 13,102 patients were included (5541 women [42%] and 7561 men [58%]; P < .001). Hamstring tendon autografts accounted for 90% (11,764 patients) of all reconstructions, of which 96% were performed with a single-bundle technique (11,339 patients). Patellar tendon autografts accounted for the remaining 10% (1338 patients). At index reconstruction, observed injuries to menisci and cartilage were common (40% and 28%, respectively). The overall 2-year incidence of revision surgery was 1.60% (women, 1.57%; men, 1.63%; P = .854). Patients with metal interference screw fixation of a semitendinosus tendon autograft on the tibia had a significantly reduced risk of early revision surgery (RR = 0.32; 95% CI, 0.12-0.90; P = .031). Conclusion: Metal interference screw fixation of a semitendinosus tendon autograft on the tibia was an independent predictor of significantly lower 2-year incidence of revision surgery. Graft selection, graft width, a single-bundle or a double-bundle technique, femoral graft fixation, the injury-to-surgery interval, and meniscus injury were not predictors of early revision surgery.
Multiple sclerosis registries in Europe – results of a systematic survey
Authors: Flachenecker Peter , Buckow Karoline , Pugliatti Maura , Kes Vanja Bašić , Battaglia Mario A , Boyko Alexey , Confavreux Christian , Ellenberger David , Eskic Danica , Ford David , Friede Tim , Fuge Jan , Glaser Anna , Hillert Jan , Holloway Edward , Ioannidou Eva , Kappos Ludwig , Kasilingam Elisabeth , Koch-Henriksen Nils , Kuhle Jens , Lepore Vito , Middleton Rod , Myhr Kjell-Morton , Orologas Anastasios , Otero Susana , Pitschnau-Michel Dorothea , Rienhoff Otto , Sastre-Garriga Jaume , Schyns-Liharska Tsveta , Sutovic Dragana , Thalheim Christoph , Trojano Maria , Vlasov Yan V , Yaldizli Özgür ,   for the EUReMS Consortium*
Published: April 2014

Background: Identification of MS registries and databases that are currently in use in Europe as well as a detailed knowledge of their content and structure is important in order to facilitate comprehensive analysis and comparison of data. Methods: National MS registries or databases were identified by literature search, from the results of the MS Barometer 2011 and by asking 33 national MS societies. A standardized questionnaire was developed and sent to the registries’ leaders, followed by telephone interviews with them. Results: Twenty registries were identified, with 13 completing the questionnaire and seven being interviewed by telephone. These registries differed widely for objectives, structure, collected data, and for patients and centres included. Despite this heterogeneity, common objectives of the registries were epidemiology ( n=10), long-term therapy outcome ( n=8), healthcare research ( n=9) and support/basis for clinical trials ( n=8). While physician-based outcome measures (EDSS) are used in all registries, data from patients’ perspectives were only collected in six registries. Conclusions: The detailed information on a large number of national MS registries in Europe is a prerequisite to facilitating harmonized integration of existing data from MS registries and databases, as well as comprehensive analyses and comparison across European populations.
Risk of relapse phenotype recurrence in multiple sclerosis
Authors: Kalincik Tomas , Buzzard Katherine , Jokubaitis Vilija , Trojano Maria , Duquette Pierre , Izquierdo Guillermo , Girard Marc , Lugaresi Alessandra , Grammond Pierre , Grand’Maison Francois , Oreja-Guevara Celia , Boz Cavit , Hupperts Raymond , Petersen Thor , Giuliani Giorgio , Iuliano Gerardo , Lechner-Scott Jeannette , Barnett Michael , Bergamaschi Roberto , Van Pesch Vincent , Amato Maria Pia , van Munster Erik , Fernandez-Bolanos Ricardo , Verheul Freek , Fiol Marcela , Cristiano Edgardo , Slee Mark , Rio Maria Edite , Spitaleri Daniele , Alroughani Raed , Gray Orla , Saladino Maria Laura , Flechter Sholmo , Herbert Joseph , Cabrera-Gomez Jose Antonio , Vella Norbert , Paine Mark , Shaw Cameron , Moore Fraser , Vucic Steve , Savino Aldo , Singhal Bhim , Petkovska-Boskova Tatjana , Parratt John , Sirbu Carmen-Adella , Rozsa Csilla , Liew Danny , Butzkueven Helmut ,   on behalf of the MSBase Study Group
Published: April 2014

Objectives: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of demographic and clinical features on this phenotype. Methods: Information about relapses was collected using MSBase, an international observational registry. Associations between relapse phenotypes and history of similar relapses or patient characteristics were tested with multivariable logistic regression models. Tendency of relapse phenotypes to recur sequentially was assessed with principal component analysis. Results: Among 14,969 eligible patients (89,949 patient-years), 49,279 phenotypically characterised relapses were recorded. Visual and brainstem relapses occurred more frequently in early disease and in younger patients. Sensory relapses were more frequent in early or non-progressive disease. Pyramidal, sphincter and cerebellar relapses were more common in older patients and in progressive disease. Women presented more often with sensory or visual symptoms. Men were more prone to pyramidal, brainstem and cerebellar relapses. Importantly, relapse phenotype was predicted by the phenotypes of previous relapses. (OR = 1.8–5, p = 10-14). Sensory, visual and brainstem relapses showed better recovery than other relapse phenotypes. Relapse severity increased and the ability to recover decreased with age or more advanced disease. Conclusion: Relapse phenotype was associated with demographic and clinical characteristics, with phenotypic recurrence significantly more common than expected by chance.
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study
Authors: Chee Cheng E. , Ashrani Aneel A. , Marks Randolph S. , Petterson Tanya M. , Bailey Kent R. , Melton L. Joseph , Heit John A. 
Published: April 2014

Key Points
VTE recurrence risk in patients with cancer can be stratified by cancer type, stage, stage progression, and presence of leg paresis. Patients with cancer at high VTE recurrence risk should be considered for secondary prophylaxis.
OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues
Authors: Wunderlich Mark , Brooks Ryan A. , Panchal Rushi , Rhyasen Garrett W. , Danet-Desnoyers Gwenn , Mulloy James C. 
Published: April 2014

Key PointsEx vivo addition of OKT3 is an economical and easy method to prevent xenogeneic GVHD and rescue patient leukemia sample xenografts. OKT3-treated whole UCB produces robust, durable hematopoietic xenografts that are indistinguishable from CD34+ grafts.
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
Authors: Wang Qifeng , Li Tao , Liu Huiming , Jia Xitang , Liu Bo , Wan Xin , Lang Jinyi 
Published: April 2014

Abstract

Purpose
To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or without chemotherapy.

Methods and Materials
In total, 197 patients with localized, advanced GEJAC received EBRT and NBT with or without chemotherapy. Radiotherapy consisted of external irradiation to a total dose of 40–54 Gy (median 50 Gy) and brachytherapy to 8–25 Gy (median 20 Gy) in two to five fractions. In total, 88 patients received chemotherapy that consisted of two cycles of a regimen with CDDP and 5FU from days l-4. The cycles were administered on days 1 and 29. MMC was given alone in bolus injection on day 1 each week. The cycles were administered on days 1, 8, 15 and 22.

Results
The duration of follow-up ranged from six to 106 months (median 30.4 months). The median survival time for the 197 patients was 13.3 months, and the one, two, three- and five-year rates for overall survival were 57.1%, 35.1%, 23.0% and 9.2%, respectively. For acute toxicity, no incidences of fistula and massive bleeding were observed during this treatment period. In total, 159 (80.7%) patients developed Grade 2 hematologic toxicity and 146 (74.1%) patients developed Grade ≥ 2 esophagitis. The median times of incidence of fistula and bleeding were 9.5 (3–27.3) months and 12.7 (5–43.4) months, respectively. The incidence of severe, late complications was related to higher NBT dose/f (20–25 Gy/5 F) and higher total dose(≥70 Gy). In total, 75.2% of the patients resumed normal swallowing and 2.0% had some residual dysphagia (non-malignant) requiring intermittent dilatation.

Conclusion
A combination of EBRT and NBT with the balloon type applicator was feasible and well tolerated. Better local-regional control and overall survival cannot achieved by a higher dose, and in contrast, a higher dose caused more severe esophageal injury.
Advancing quantitative description of porosity in autogenous laser-welds of 304L stainless steel
Authors: Madison Jonathan D , Aagesen Larry K , Chan Victor WL , Thornton Katsuyo 
Published: April 2014

AbstractPorosity in linear autogenous laser welds of 304L stainless steel has been investigated using micro-computed tomography to reveal defect content in fifty-four welds made with varying delivered power, travel speed and focal lens. Trends associated with porosity size and frequencies are shown and interfacial measures are employed to provide quantitative descriptors of pore shape, directionality, interspacing and solid linear fraction. Lastly, the coefficient of variation associated with equivalent pore radii is reported toward a discussion of microstructural variability and the influence of process-parameters on such variability.
Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis
Authors: Li Chun , Mu Rong , Guo Jianping , Wu Xinyu , Tu Xin , Liu Xu , Hu Fanlei , Guo Shiwei , Zhu Jiaxin , Xu Huji , Li Zhanguo 
Published: April 2014

Abstract
Introduction
Interleukin (IL)-33 is a proinflammatory cytokine contributing to the pathogenesis of rheumatoid arthritis (RA). The gene encoding IL-33 may serve as a genetic factor and be associated with the risk of RA. To investigate the potential association between IL33 and RA, we performed a case–control study based on Chinese Han population.

Methods
A three-stage case–control study was performed. Two tag single-nucleotide polymorphisms (SNPs) (rs7044343 and rs10975514), mapping to the IL33 gene, were first genotyped in the discovery population. We further genotyped rs7044343 and rs10975514 in the validation and replication population. The associations between the two tag SNPs and phenotypic subgroups of RA and levels of serum IL-33 were assessed with a logistic regression model.

Results
In the discovery population, the CC genotype of rs7044343 was associated with RA patients (odds ratio (OR) = 0.777, 95% confidence interval (CI), 0.611 to 0.988; P = 0.040). After anti-citrullinated peptide antibody (ACPA) stratification, the CC genotype of rs7044343 was also shown to be a protective genotype in RA without ACPA (OR = 0.610; 95% CI, 0.379 to 0.982; P = 0.042). In the validation population and replication population, the association between rs7044343 and RA, especially ACPA-negative RA, was still significant. A meta-analysis of discovery, validation, and replication panels confirmed the association between CC genotype of rs7044343 and RA (Pcombined = 0.0004; ORcombined = 0.77; 95% CI, 0.67 to 0.89). No evidence was found for heterogeneity between three sample sets (P
het
= 0.99; I2 = 0%). Similar results were also obtained in ACPA-negative RA (Pcombined = 0.0002; ORcombined = 0.57; 95% CI, 0.43 to 0.77). No association was detected between rs10975514 polymorphism and RA susceptibility in the discovery and validation population. The serum levels of IL-33 were significantly lower in the patients with the rs7044343 CC genotype.

Conclusion
The CC genotype of rs7044343 in IL33 is associated with RA patients and downregulates IL-33 expression in RA.
Effect of intensive care after cardiac arrest on patient outcome: a database analysis
Authors: Schober Andreas , Holzer Michael , Hochrieser Helene , Posch Martin , Schmutz Rene , Metnitz Philipp 
Published: April 2014

Abstract
Introduction
The study aimed to determine the impact of treatment frequency, hospital size, and capability on mortality of patients admitted after cardiac arrest for postresuscitation care to different intensive care units.

Methods
Prospectively recorded data from 242,588 adults consecutively admitted to 87 Austrian intensive care units over a period of 13 years (1998 to 2010) were analyzed retrospectively. Multivariate analysis was used to assess the effect of the frequency of postresuscitation care on mortality, correcting for baseline parameters, severity of illness, hospital size, and capability to perform coronary angiography and intervention.

Results
In total, 5,857 patients had had cardiac arrest and were admitted to an intensive care unit. Observed hospital mortality was 56% in the cardiac-arrest cohort (3,302 nonsurvivors). Patients treated in intensive care units with a high frequency of postresuscitation care generally had high severity of illness (median Simplified Acute Physiology Score (SAPS II), 65). Intensive care units with a higher frequency of care showed improved risk-adjusted mortality. The SAPS II adjusted, observed-to-expected mortality ratios (O/E-Ratios) in the three strata (<18; 18 to 26; >26 resuscitations per ICU per year) were 0.869 (95% confidence interval, 0.844 to 894), 0.876 (0.850 to 0.902), and 0.808 (0.784 to 0.833).

Conclusions
In this database analysis, a high frequency of post-cardiac arrest care at an intensive care unit seemed to be associated with improved outcome of cardiac-arrest patients. We were able to identify patients who seemed to profit more from high frequency of care, namely, those with an intermediate severity of illness. Considering these findings, cardiac-arrest care centers might be a reasonable step to improve outcome in this specific population of cardiac-arrest patients.
Management of Pseudomonas aeruginosa pneumonia: one size does not fit all
Authors: Rello Jordi , Borgatta Bárbara , Lagunes Leonel 
Published: April 2014

AbstractIn view of the mortality associated with Pseudomonas aeruginosa (PSA) ventilator-associated pneumonia (VAP) and the frequency of inadequate initial empiric therapy, recent findings underscore the need for a different management paradigm with effective anti-pseudomonal vaccines for prophylaxis of patients at risk. The association of virulence factors is a variable that splits PSA in two phenotypes, with the possibility of adjunctive immunomodulatory therapy for management of virulent strains. We comment on recent advances in and the state of the art of PSA-VAP management and discuss a new paradigm for tailored and optimal management.
A genome scale overexpression screen to reveal drug activity in human cells
Authors: Arnoldo Anthony , Kittanakom Saranya , Heisler Lawrence E , Mak Anthony B , Shukalyuk Andrey I , Torti Dax , Moffat Jason , Giaever Guri , Nislow Corey 
Published: April 2014

AbstractTarget identification is a critical step in the lengthy and expensive process of drug development. Here, we describe a genome-wide screening platform that uses systematic overexpression of pooled human ORFs to understand drug mode-of-action and resistance mechanisms. We first calibrated our screen with the well-characterized drug methotrexate. We then identified new genes involved in the bioactivity of diverse drugs including antineoplastic agents and biologically active molecules. Finally, we focused on the transcription factor RHOXF2 whose overexpression conferred resistance to DNA damaging agents. This approach represents an orthogonal method for functional screening and, to our knowledge, has never been reported before.
Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial
Authors: Spathis Anna , Fife Kate , Blackhall Fiona , Dutton Susan , Bahadori Ronja , Wharton Rose , O'Brien Mary , Stone Patrick , Benepal Tim , Bates Nick , Wee Bee 
Published: April 2014

Purpose Fatigue is a distressing symptom occurring in more than 60% of patients with cancer. The CNS stimulants modafinil and methylphenidate are recommended for the treatment of cancer-related fatigue, despite a limited evidence base. We aimed to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with non–small-cell lung cancer (NSCLC). Patients and Methods Adults with advanced NSCLC and performance status of 0 to 2, who were not treated with chemotherapy or radiotherapy within the last 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo. The primary outcome was change in Functional Assessment of Chronic Illness Therapy (FACIT) –Fatigue score from baseline to 28 days, adjusted for baseline fatigue and performance status. Secondary outcomes included safety and patient-reported measures of depression, daytime sleepiness, and quality of life. Results A total of 208 patients were randomly assigned, and 160 patients (modafinil, n = 75; placebo, n = 85) completed questionnaires at both baseline and day 28 and were included in the modified intention-to-treat analysis. FACIT-Fatigue scores improved from baseline to day 28 (mean score change: modafinil, 5.29; 95% CI, 2.57 to 8.02; placebo, 5.09; 95% CI, 2.54 to 7.65), but there was no difference between treatments (0.20; 95% CI, −3.56 to 3.97). There was also no difference between treatments for the secondary outcomes; 47% of the modafinil group and 23% of the placebo group stated that the intervention was not helpful. Conclusion Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting. Its use was associated with a clinically significant placebo effect.